Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

504.96 +2.25 (+0.45%)

Streaming Delayed Price Updated: 12:53 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗

September 02, 2025

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Via Investor's Business Daily

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗

August 27, 2025

Via Stocktwits

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Preview: United Therapeutics's Earnings ↗

July 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

September 02, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corp. (NASDAQ:UTHR) Embodies Peter Lynch's GARP Strategy ↗

August 27, 2025

United Therapeutics (UTHR) exemplifies Peter Lynch's GARP strategy with strong EPS growth, zero debt, and an undervalued PEG ratio. A model for long-term investors.

Via Chartmill

2 Mid-Cap Stocks with Competitive Advantages and 1 Facing Headwinds

August 27, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

3 Market-Beating Stocks to Consider Right Now

August 26, 2025

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

Via StockStory

2 Profitable Stocks to Keep an Eye On and 1 That Underwhelm

August 25, 2025

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

August 19, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Growth Stock to Stash and 2 Facing Challenges

August 19, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Prime Value Investment with Strong Fundamentals and Undervalued Potential ↗

August 15, 2025

UNITED THERAPEUTICS CORP (UTHR) is a strong value investing pick with low P/E ratios, zero debt, and high profitability, trading below its true worth. Ideal for investors seeking undervalued biotech...

Via Chartmill

UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty

August 12, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per...

Via StockStory

Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It ↗

August 12, 2025

The company is working through a patent battle that could seriously hamper sales of its new drug.

Via Investor's Business Daily

Topics Intellectual Property

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen ↗

August 09, 2025

United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors.

Via Chartmill

Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy ↗

August 06, 2025

UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech...

Via Chartmill

Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility

August 04, 2025

Joby Aviation (NYSE: JOBY) has recently experienced a significant surge in its stock value, fueled by a burgeoning "aviation buzz" surrounding the electric vertical takeoff and landing (eVTOL) aircraft...

Via MarketMinute

Topics Economy Emissions

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

August 01, 2025

From United Therapeutics Corporation

Via Business Wire

Forecasting The Future: 8 Analyst Projections For United Therapeutics ↗

July 31, 2025

Via Benzinga

Earnings Summary on United Therapeutics ↗

July 31, 2025

Via The Motley Fool

Topics Intellectual Property

United Therapeutics Stock Slides On Q2 Earnings: The Details ↗

July 30, 2025

United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report.

Via Benzinga

United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates

July 30, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per share...

Via StockStory

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results

July 30, 2025

From United Therapeutics Corporation

Via Business Wire

What To Expect From United Therapeutics’s (UTHR) Q2 Earnings

July 28, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗

July 24, 2025

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.

Via Investor's Business Daily

UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential ↗

July 24, 2025

UNITED THERAPEUTICS CORP (UTHR) is a top value stock with strong fundamentals—low P/E, high profitability, zero debt, and steady growth—making it a standout in biotech.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.